DeCure's autonomous Metabolic AI scientist is researching a drug-repurposing hypothesis for abdominal obesity-metabolic syndrome 4 — screening already-approved drugs against its 1-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleAbdominal obesity-metabolic syndrome 4 maps to a 1-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for abdominal obesity-metabolic syndrome 4 is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
What the evidence adds up to
A 2024 review of 18 adult obesity treatment guidelines found broad agreement on patient evaluation, lifestyle intervention, and the role of metabolic and bariatric surgery, which remains the most durable treatment; newer guidelines recommend surgery at lower BMI thresholds for people with uncontrolled type 2 diabetes. The guidelines diverge on preferred anti-obesity medications, and the authors note updates are needed to incorporate new treatment innovations.
Earlier reviews are more cautious. A 2007 review states that drugs then available for obesity and metabolic syndrome were few and limited in efficacy, and a 2015 review notes that many earlier anti-obesity drugs were withdrawn from the market and that drugs in present use lack sufficient long-term efficacy and safety data. A 2004 meeting report concluded that a highly effective agent for metabolic syndrome had yet to be developed, though it identified a few promising molecular targets from a broad spectrum of potential mechanisms.
A 2009 Spanish-language review of metabolic syndrome and stroke recommends comprehensive medical treatment targeting the syndrome through simultaneous management of its individual components, with lifestyle modification as the foundation and pharmacological treatment considered when necessary. No single drug is presented as a solution for the cluster of risk factors.
What is still missing: long-term efficacy and safety data for current anti-obesity drugs, updated regulatory guidelines for new treatment options, and a single agent that effectively treats all components of metabolic syndrome rather than each risk factor separately.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Diabetes Spectrum · 2024 · 19 citations · open access
A Guideline-Directed Approach to Obesity Treatment
AbstractThis article summarizes and compares 18 sets of guidelines for adult obesity treatment, highlighting key recommendations for patient evaluation, lifestyle intervention, anti-obesity medications (AOMs), and metabolic and bariatric surgery. Guidelines are consistent in many regards, although there is divergence regarding preferred AOMs. Metabolic and bariatric surgery is still recognized as the most durable form of obesity treatment, and newer guidelines suggest these procedures at lower BMI thresholds for people with uncontrolled type 2 diabetes. Overall, guidelines for obesity treatment show a high degree of agreement, although updates are needed to incorporate new treatment innovations.
Síndrome metabólico y enfermedad vascular cerebral: evidencias en su tratamiento
AbstractINTRODUCTION: Stroke (cerebrovascular disease) is the leading cause of disability and the third of death worldwide. It is considered an age-related disease, although there are several modifiable risk factors, including the simultaneous and frequent combination of obesity, hypertension, dyslipidaemia and elevated fast glucose, which has been labeled the metabolic syndrome; nowadays, it is associated with generalized and brain atherosclerosis. DEVELOPMENT: It is analyzed here how both different components of metabolic syndrome and metabolic syndrome itself are important risk factors for suffering stroke, one by one and all grouped together as well. Based on the best available clinical evidence, appropriated medical management strategies are proposed (evidence-based treatment). CONCLUSIONS: It is proposed a comprehensive medical treatment approach, targeted on the metabolic syndrome trough simultaneous management of individual components; currently, modifications in lifestyle (increasing exercise, weight reduction and diet) are recommended; besides, based on the best available evidence, pharmacological treatment should be considered when necessary.
AbstractObesity is increasing in prevalence and its medical liabilities are largely related to central adiposity and the associated insulin resistance. The present drugs available for the treatment of obesity and metabolic syndrome are few in number and limited in efficacy. This chapter reviews the drugs approved by the US Food and Drug Administration (FDA) to treat obesity, drugs approved by the FDA for other indications than weight loss, drugs in the late development process that have not been approved by the FDA, drugs in earlier stages of drug development for which clinical information is limited, drugs that have been dropped from development, and new potential drug targets for which essentially no clinical data yet exist. We also review the nonprescription products sold for the treatment of obesity and metabolic syndrome. The developmental pipeline of drugs for the treatment of obesity and the metabolic syndrome is rich. Because drugs to treat obesity are being developed in an era characterized by more sophisticated tools for drug development than existed when hypertension drugs were being developed, much faster progress in developing safe and effective drugs for obesity and metabolic syndrome is anticipated. With safe and effective drugs available, we anticipate that the chronic treatment of obesity with weight loss medication will become as well-accepted and prevalent as is the chronic drug treatment of hypertension and diabetes in the medical practice of today.
Obesity Context of Type 2 Diabetes and Medication Perspectives
AbstractAbstract Drug therapy of obesity has harsh antecedent that many earlier introduced drugs are withdrawn from market. The drugs in present use lack sufficient long-term efficacy and safety data. The difficulty of reversing changing dietary habits and decline in physical activity, however, offers major scope for anti-obesity therapeutics, implied in managing the epidemic chronic inflammatory maladies and cardiovascular sequel. Metabolic syndrome, pre-diabetes and type 2 diabetes mellitus, commonly associate with obesity. Weight reduction is crucial to prevent and control type 2 diabetes. This emphasizes rational choice of therapeutic regimens that do not themselves cause weight gain, and better promote weight loss. Such an aspect is addressed briefly focusing upon the available newer anti-obesity drug options, in particular.
Expert Opinion on Investigational Drugs · 2004 · 3 citations
Targeting Metabolic Syndrome
AbstractMetabolic syndrome has been recognised as a cluster of risk factors contributing to the development of cardiovascular diseases. Different diagnostic criteria have been proposed and the consensus focuses on four major risk factors: obesity, diabetes, dyslipidaemia and hypertension. Although treatment options are available to treat each component separately, a highly effective agent for metabolic syndrome has yet to be developed. To explore the clinical definition of metabolic syndrome and potential molecular targets that can be modulated for treatment purpose, a meeting entitled 'Targeting Metabolic Syndrome' was organised in 2004 by IBC USA Conferences, Inc. This article highlights discussions related to the clinical correlates and pathophysiology of metabolic syndrome, and reviews some of the promising drug discovery efforts. Metabolic syndrome should be treatable and preventable if obesity and insulin resistance are well controlled. New regulatory guidelines need to be developed as new treatment options are being investigated. From a broad spectrum of potential mechanisms encompassing central nervous system targets and peripheral targets for pharmacological intervention, a few promising molecular targets have emerged. Modulating these is expected to treat at least some components of metabolic syndrome.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
